
Cardiovascular Systems CSII
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Deferred Revenue 2011-2026 | CSII
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.11 M | 2.4 M | 1.87 M | 1.76 M | 1.24 M | - | - | - | 59 K | 156 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 59 K | 1.37 M |
Quarterly Deferred Revenue Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 525 K | 694 K | 2.11 M | 2.81 M | 2.72 M | 2.49 M | 2.4 M | 2.4 M | 2.08 M | 2.09 M | 1.87 M | 1.76 M | 1.66 M | 1.71 M | 1.76 M | 1.76 M | 1.52 M | 1.25 M | 1.24 M | 1.24 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.81 M | 525 K | 1.77 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Eargo
EAR
|
311 K | - | - | $ 10.2 M | ||
|
IRIDEX Corporation
IRIX
|
2.16 M | $ 1.01 | - | $ 17.1 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
1.67 M | $ 11.44 | -2.22 % | $ 324 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 8.27 | 0.49 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 4.3 | -2.27 % | $ 161 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 73.83 | 0.26 % | $ 4.03 B | ||
|
LENSAR
LNSR
|
2.6 M | $ 6.09 | 2.35 % | $ 72.8 M | ||
|
Helius Medical Technologies
HSDT
|
27 K | $ 2.29 | -2.97 % | $ 50.5 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
182 K | $ 0.46 | 0.17 % | $ 28.6 M | ||
|
Delcath Systems
DCTH
|
170 K | $ 11.02 | -3.76 % | $ 395 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Pulmonx Corporation
LUNG
|
18 K | $ 1.55 | 0.65 % | $ 63.1 M | ||
|
Myomo
MYO
|
2.51 K | $ 1.04 | 9.5 % | $ 43.5 M | ||
|
Butterfly Network
BFLY
|
26.9 M | $ 4.47 | -0.11 % | $ 1.1 B | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
4.72 K | $ 2.39 | 3.91 % | $ 6.63 M | ||
|
Profound Medical Corp.
PROF
|
445 K | $ 6.83 | -2.01 % | $ 206 M | ||
|
Globus Medical
GMED
|
27.7 M | $ 84.81 | 0.24 % | $ 11.5 B | ||
|
Insulet Corporation
PODD
|
14 M | $ 154.87 | -1.29 % | $ 10.9 B | ||
|
Integer Holdings Corporation
ITGR
|
5.21 M | $ 89.28 | -0.8 % | $ 3.1 B | ||
|
TransMedics Group
TMDX
|
2.9 M | $ 68.94 | 0.12 % | $ 2.34 B | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M |